On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Lexicon Pharmaceuticals, (NASDAQ:LXRX), Perrigo Company (NYSE:PRGO), Kite Pharma (NASDAQ:KITE), Norfolk Southern (NYSE:NSC)
Perrigo Company plc Ordinary Shares (NYSE:PRGO) decreased -3.76%, and closed at $166.37. The company holds the market capitalization of $24.34 M. For the last twelve months, the stock was able to keep return on equity at 3.90%, while return on assets at 2.40%, in response to its return on investment at 2.80%. Its 20-day moving average gained 2.99%, Above 50-day moving average of 5.26%, above 200-day moving average of 8.55% from the latest market price of $166.37. The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).
Perrigo Company plc Ordinary Shares (PRGO) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) declined -3.64%, and closed at $1.06. The company has the market capitalization of $797.66 million. The beta value of the stock is 1.84. On the other hand the stock’s volatility for the week is 3.69%, and for the month is 4.84%. The stock’s price to book ratio is $2.21, however price to sale ratio is $33.57. Analyst’s mean recommendation regarding this stock is 2.10. (Where 1=Buy, 5=Sale).
Lexicon Pharmaceuticals, Inc. (LXRX) through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services.
Kite Pharma Inc (NASDAQ:KITE) decreased -3.62%, and closed at $69.29.Price to book ratio is 13.75. With recent decline, the year-to-date (YTD) performance reflected a 23.86% incline below last year. During the past month the stock gain 5.72%, bringing three-month performance to 34.52% and six-month performance to 165.58%. The mean recommendation of analysts for this stock is 1.40 (where 1=Buy, 5=Sale).
Kite Pharma Inc (KITE) operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma.
Norfolk Southern Corp. (NYSE:NSC) shares picked down -3.50%, and closed at $106.56. The stock volatility for the week is 1.77%, while for the month remained 1.23%. The company holds consensus target price of $113.92.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 6.41 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 5.60% and Annual EPS growth for the past 5 years is considered as 18.20%.
The mean recommendation of analysts for this stock is 2.40. (Where 1=Buy, 5=Sale).
Norfolk Southern Corp. (NSC) together with its subsidiaries, engages in the rail transportation of raw materials, intermediate products, and finished goods. As of December 31, 2014, it operated approximately 20,000 miles of road in 22 states and the District of Columbia. The company also operates scheduled passenger trains; transports overseas freight through various Atlantic and Gulf Coast ports; and provides logistics services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
